Intramyocellular lipid excess in the mitochondrial disorder MELAS
MRS determination at 7T

Sailaja Golla, MD
Jimin Ren, PhD
Craig R. Malloy, MD
Juan M. Pascual, MD, PhD

Correspondence to Dr. Pascual:
Juan.Pascual@UTSouthwestern.edu

ABSTRACT
Objective: There is a paucity of objective, quantifiable indicators of mitochondrial disease available for clinical and scientific investigation.

Methods: To this end, we explore intramyocellular lipid (IMCL) accumulation noninvasively by 7T magnetic resonance spectroscopy (MRS) as a reporter of metabolic dysfunction in MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes). We reasoned that mitochondrial dysfunction may impair muscle fat metabolism, resulting in lipid deposition (as is sometimes observed in biopsies), and that MRS is well suited to quantify these lipids.

Results: In 10 MELAS participants and relatives, IMCL abundance correlates with percent mitochondrial DNA mutation abundance and with disease severity.

Conclusions: These results indicate that IMCL accumulation is a novel potential disease hallmark in MELAS. Neurology Genet 2017;3:e160; doi: 10.1212/NXG.0000000000000160

GLOSSARY
ATP = adenosine triphosphate; IMCL = intramyocellular lipid; MRS = magnetic resonance spectroscopy; mtDNA = mitochondrial DNA; ppm = parts per million; TE = echo time.

Proper diagnosis and effective monitoring of patients with mitochondrial diseases remains a challenge in part because plasma and urine metabolite concentrations are nonspecific, tissue biopsies have limited acceptability and are prone to sampling error, and longitudinal measurements with invasive procedures are difficult.1

MELAS syndrome (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes) is a maternally inherited and relatively prevalent mitochondrial disorder. Multiple studies have reported magnetic resonance spectroscopy (MRS) findings in the brain including elevated lactate, but studies of metabolism in skeletal muscle by MRS methods have been limited. For example, a combined examination with 31P and 1H NMR spectroscopy has characterized mitochondrial function and intramyocellular lipids (IMCLs) in one individual with MELAS.2 This study points to the advantages of MRS in examinations of patients with suspected mitochondrial disorders—subject acceptability, safety, and detailed metabolic information specific to an organ.

The purpose of this study was to examine the feasibility of 1H MRS at 7 Tesla (7T) in MELAS participants and maternal relatives. We separately determined normal IMCL in healthy controls; results were compared with an earlier cohort of healthy controls. In MELAS, a robust correlation was found between IMCL abundance and percent A3243G mutant mitochondrial DNA (mtDNA) abundance in the blood. The study was well tolerated by all participants. The high chemical shift dispersion at 7T was advantageous because the IMCL and other metabolite

From the Rare Brain Disorders Program (S.G., J.M.P.), Department of Neurology and Neurotherapeutics, Department of Pediatrics (S.G., J.M.P.), Advanced Imaging Research Center (J.R., C.R.M.), Department of Radiology (J.R., C.R.M.), Department of Internal Medicine (C.R.M.), Department of Physiology (J.M.P.), and Eugene McDermott Center for Human Growth & Development/Center for Human Genetics (J.M.P.), The University of Texas Southwestern Medical Center, Dallas.

Funding information and disclosures are provided at the end of the article. Go to Neurology.org/ng for full disclosure forms. The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
signals were easily resolved. Thus, $^1\text{H}$ MRS at 7T may provide an avenue for investigating disease severity as well as the response of skeletal muscle to therapies.

**METHODS**

**Standard protocol approvals, registrations, and patient consents.** This study was approved by the Institutional Review Board of the University of Texas Southwestern Medical Center. Informed written consent was obtained from all participants or their legal guardians as appropriate. They were studied over 4 months in one visit (each lasting less than 3 hours).

**General methods.** Mutant mtDNA abundance (expressed as percent of mutant DNA relative to total blood DNA) was routinely determined in the blood by quantitative PCR. Because mutation abundance can vary with age by 0.6%–1.9% per year in each person, participants were genotyped within 3 years preceding enrollment. All participants’ symptoms and medical history were obtained using a standardized questionnaire. Complete hemato logic, endocrine, chemical, and lipid profiles (including blood cell count, blood electrolytes, transaminases, lactate, urea nitrogen, creatinine, amino acids, creatine kinase, free fatty acids, thyroid-stimulating hormone, T4, lipid panel [total, low-density lipoprotein and high-density lipoprotein cholesterol, and triglycerides], fasting blood glucose, and hemoglobin A1c [HbA1c]) were measured by standard clinical laboratory methods and compared with normal values established in each laboratory.

**Skeletal muscle proton MRS.** The details of the examination have been published. Briefly, leg calf muscles of rested (>2 hours) participants were subject to MRS in a 7T system (Achieva; Philips Medical Systems, Cleveland, OH) without sedation. Scan sessions lasted less than 1 hour. Participants were positioned supine with their legs parallel to the magnetic field and the left calf sitting on the center of a partial volume quadrature transmit/receive coil customized to fit the shape of a human calf. Axial, coronal, and turbo spin-echo images were first acquired to guide voxel placement within the soleus muscle. Single-voxel $^1\text{H}$ MRS spectra were collected from the soleus with a volume of 3 mL, using a STimulated Echo Acquisition Mode (STEAM) sequence, at long echo time (TE) of both 140 and 280 milliseconds, and a constant repetition time of 2 seconds. A typical number of scans were 192 (or 6.4 minutes for TE 140 milliseconds) and 256 (or 8.5 minutes for TE 280 milliseconds). No water suppression pulses were applied during data acquisition to avoid signal reduction due to possible magnetization-transfer effects on metabolites as we previously described. The $^1\text{H}$ chemical shifts of all metabolite resonances arising from muscle were referenced to creatine methyl protons set to 3.02 parts per million (ppm) (Cr3). The area of each metabolite $^1\text{H}$ resonance signal was determined by fitting the spectrum to a Voigt lineshape (variable proportions of lorentzian plus gaussian) using ACD software (Advanced Chemistry Development, Inc., Toronto, ON, Canada). The asymmetry of the extramyocellular lipid signal was fitted by 2 Voigt lineshapes as described.

**RESULTS**

All the participants tested positive for the m.3243A>G mutation except those identified as maternal relatives (table). As a group, the MELAS participants exhibited the common features of the disorder such as lactic acidosis, stroke-like episodes, hearing loss, neuropathy and, in some, diabetes as indicated in the table. Elevated IMCLs were observed in all the MELAS participants examined by MRS (figure 1). Of the 8 participants with MELAS (table), the average concentration of IMCLs was 26 ± 18 mmol/kg muscle mass. The average concentration of IMCL among participants with the more severe phenotype (participants 4, 7, 8, and 10) tended to be higher, 33 mmol/kg muscle mass. The association between IMCL abundance and percent mutant mtDNA abundance depended on the coexistence of diabetes (figure 2).

The ratio of the trimethylamine signal from carnitine at 3.20 ppm relative to the creatine methyl signal at 3.02 ppm (carnitine/Cr3) is typically <1 or ∼1;
the relative signals are sensitive to acquisition conditions. With a TE of 140 milliseconds, the signals are typically ~1:1 or nearly equally sized “twin peaks.” MELAS participants displayed significantly higher trimethylamine/Cr3 ratio (1.46 ± 0.40).

The relation between IMCL and plasma lactate, urea nitrogen, creatinine, free fatty acids, triglycerides, and total cholesterol was also examined. No significant correlation was found.

**DISCUSSION** There is a paucity of biomarkers and of noninvasive methods available for the study of mitochondrial disorders. These obstacles limit clinical trials. For example, our study of dichloroacetate (a lactate-reducing drug) in a mitochondrial disorder was discontinued when toxic neuropathy was detected by nerve conduction monitoring despite the appearance of subjective benefits such as increased physical endurance. A key limitation is the difficulty of acquiring objective measurements of metabolic efficacy in the target tissue.

Our study demonstrated an increase in the concentration of IMCLs among participants with MELAS syndrome compared with historical healthy controls. A simple explanation is that skeletal mitochondrial function in MELAS is substantially impaired, resulting in diminished oxidation of fatty acids and accumulation of IMCL in the cytosol. Among the cytoplasmic lipids that accumulate in relation to metabolic dysfunction are diacylglycerol and ceramide. Extensive evidence links these lipids with human mitochondrial dysfunction and with

---

**Figure 1** Proton spectra of skeletal muscle

MRS of 2 soleus muscles (participants 1 [A] and 2 [B]). Proton spectra were acquired at 2 echo times as described in the text. Solid black lines are plots of the spectra. IMCL CH2 represents resonances attributed to intramyocellular lipids, whereas EMCL CH2 is considered to arise from extramyocellular lipids. Carnitine CH3 = signal arising from carnitine; creatine CH3 = signal emanating from carbon 3 of creatine; H2O = water spectrum; MRS = magnetic resonance spectroscopy; ppm = parts per million.

---

**Figure 2** IMCL, mtDNA, and diabetes correlations

IMCL abundance correlations with percent mutant mtDNA (m.A3243G) in the blood. (A) Correlations for nondiabetic (i.e., HbA1c <6% and no history of diabetes) participants. (B) Correlations for diabetic participants (HbA1c >6% and a history of diabetes). Correlation coefficients with a straight line are given in each panel. IMCL = intramyocellular lipid; mtDNA, mitochondrial DNA.
mitochondrial-related insulin resistance. For example, in diabetes, slowed postexercise mitochondrial adenosine triphosphate (ATP) resynthesis is related to increased insulin resistance, whereas insulin-stimulated rates of mitochondrial ATP synthesis are reduced in otherwise healthy insulin-resistant participants. Accumulation of these lipids has also been observed by MRS in relation to insulin resistance in otherwise healthy and diabetic participants. An earlier case report did not find a significant increase in IMCL in a single participant using skeletal water as an internal reference and a TE of 30 milliseconds. This study used relatively long echo times to suppress water signal, so differences in acquisition and quantitation methods may be important.

This study found an unexpected increase in the carnitine/creatine ratio. Because this MRS method only detects the ratio of NMR-visible metabolites and not absolute concentration, this altered ratio could be due to some combination of altered relaxation times, increased carnitine, decrease creatine, or some combination of these factors. Further studies will clarify any potential racial differences in IMCL abundance in relation to insulin resistance in MELAS and the presence of IMCL in other mitochondrial diseases.

AUTHOR CONTRIBUTIONS

STUDY FUNDING
This work was supported by a pilot grant to J.M.P. and C.R.M. under NIH grant UL1TR001105 and by a gift of the Hegi Foundation to Children’s Medical Center Dallas to support the work of S.G. and J.M.P. J.M.P. and C.R.M. are also supported by NIH grants NS077015, NS078059, EB015908, and RR024982.

DISCLOSURE
Dr. Golla reports no disclosures. Dr. Ren has served on the editorial boards of the Journal of Analytical & Molecular Techniques, BioMed Research International, and Current Metabolomics. Dr. Malloy has served on the editorial board of Tomography and has received publishing royalties for writing occasional book chapters (<$100). Dr. Pascual has served on the editorial board of Neuroscience Letters and has received research support from NIH/National Institute of Neurological Disorders and Stroke and NIH/NIMH. Go to Neurology.org/ng for full disclosure forms.

Received March 6, 2017. Accepted in final form April 7, 2017.

REFERENCES
Intramyocellular lipid excess in the mitochondrial disorder MELAS: MRS determination at 7T
Sailaja Golla, Jimin Ren, Craig R. Malloy, et al.

Neurol Genet 2017;3; DOI 10.1212/NXG.0000000000000160

This information is current as of May 25, 2017